for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novavax, Inc.

NVAX.O

Latest Trade

141.55USD

Change

6.56(+4.86%)

Volume

7,942,656

Today's Range

140.23

 - 

156.32

52 Week Range

76.59

 - 

331.68

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Novavax Reconfirms Confidence In Regulatory Filing Timelines And Manufacturing Quality

Oct 20 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX RECONFIRMS CONFIDENCE IN REGULATORY FILING TIMELINES AND MANUFACTURING QUALITY.NOVAVAX INC - GLOBAL SUPPLY CHAIN IS EXPECTED TO ACHIEVE A CAPACITY OF 150 MILLION DOSES PER MONTH BY END OF FOURTH QUARTER.NOVAVAX INC - EXPECT TO COMPLETE MULTIPLE ONGOING ROLLING REGULATORY SUBMISSIONS FOR COVID-19 VACCINE WITHIN NEXT COUPLE OF WEEKS IN KEY MARKETS.NOVAVAX INC - EXPECT TO FILE FOR EMERGENCY USE AUTHORIZATION FOR COVID-19 VACCINE IN THE U.S. BEFORE THE END OF 2021.Further company coverage: NVAX.O. ((Reuters.Briefs@thomsonreuters.com;)).

Novavax Says Prevent-19 (Us/Mex Phase 3) Results Were Submitted For Publication

Oct 11 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX ANNOUNCE THAT PREVENT-19 (US/MEX PHASE 3) RESULTS WERE SUBMITTED FOR PUBLICATION - TWEET.NOVAVAX SAYS EFFICACY AGAINST MODERATE-TO-SEVERE COVID-19 WAS 100%, AND EFFICACY AGAINST SEVERE DISEASE ALONE WAS 100% (POST-HOC) - TWEET.NOVAVAX-PRIMARY ENDPOINT EFFICACY OF NVX-COV2373 IN PREVENTING RT-PCR-CONFIRMED, SYMPTOMATIC MILD, MODERATE OR SEVERE COVID19 ONSET≥7 DAYS AFTER SECOND DOSE.NOVAVAX SAYS EFFICACY AMONGST HIGH-RISK POPULATIONS WAS 91% - TWEET.NOVAVAX- NO SAFETY CONCERNS RELATED TO VACCINATION WERE SEEN.NOVAVAX- EFFICACY AGAINST NON-VOI/VOC WAS 100%, EFFICACY AGAINST ANY VOI/VOC WAS 92.6% IN TRIAL.

Mabion Signs $372 Commercial Scale Production Deal With Novavax

Oct 8 (Reuters) - Mabion SA <MABP.WA>::SAYS SIGNS COMMERCIAL SCALE PRODUCTION DEAL WITH NOVOVAX.SAYS TOTAL VALUE OF AGREEMENT IS $372 MLN.SAYS DEAL TO RUN FROM 2022-2025.SAYS WILL PRODUCE ANTIGENE FOR COVID-19 VACCINE.SAYS DEAL IS UNCONDITIONAL AND IS NOT DEPENDENT ON VACCINE REGISTRATION PROCEDURES.SAYS DEAL IS TO BE CARRIED OUT AND SETTLED ON A PER BATCH BASIS FOR AN AGREED PRICE PER SERIES.SAYS COMMERCIAL SCALE MANUFACTURING IN GMP STANDARD TO START IN DEC.

Novavax Announces Leadership Appointment And Updates

Oct 4 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX ANNOUNCES LEADERSHIP APPOINTMENT AND UPDATES.NOVAVAX INC - DENNY KIM APPOINTED SENIOR VICE PRESIDENT, CHIEF SAFETY OFFICER.NOVAVAX INC - DENNY KIM JOINS CO FROM J&J, WHERE HE WAS PART OF OFFICE OF CHIEF MEDICAL OFFICER.

Results From Novavax Nanoflu Influenza Vaccine Phase 3 Clinical Trial Published In Lancet Infectious Diseases

Sept 23 (Reuters) - Novavax Inc <NVAX.O>::RESULTS FROM NOVAVAX NANOFLU INFLUENZA VACCINE PHASE 3 CLINICAL TRIAL PUBLISHED IN LANCET INFECTIOUS DISEASES.NOVAVAX - RESULTS FROM NANOFLU INFLUENZA VACCINE PHASE 3 CLINICAL TRIAL ACHIEVED ALL PRIMARY ENDPOINTS.NOVAVAX INC - NANOFLU VACCINE CANDIDATE INDUCED SIGNIFICANTLY ENHANCED CELL-MEDIATED IMMUNE RESPONSES.NOVAVAX INC - NANOFLU WAS WELL-TOLERATED WITH A COMPARABLE SAFETY PROFILE.

Novavax And Serum Institute Of India Announce Submission To World Health Organization For Emergency Use Listing Of Novavax' Covid-19 Vaccine

Sept 23 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX AND SERUM INSTITUTE OF INDIA ANNOUNCE SUBMISSION TO WORLD HEALTH ORGANIZATION FOR EMERGENCY USE LISTING OF NOVAVAX' COVID-19 VACCINE.NOVAVAX INC - SUBMISSION TO WHO IS BASED ON COMPANIES' PREVIOUS REGULATORY SUBMISSION TO DRUGS CONTROLLER GENERAL OF INDIA(DCGI).

Novavax Initiates Phase 1/2 Trial Of Combination Vaccine For COVID-19 And Seasonal Influenza

Sept 8 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX INITIATES PHASE 1/2 CLINICAL TRIAL OF COMBINATION VACCINE FOR COVID-19 AND SEASONAL INFLUENZA.NOVAVAX INC - FIRST PARTICIPANTS ENROLLED IN PHASE 1 CLINICAL TRIAL OF COMBINATION NANOFLU™/NVX-COV2373 VACCINE WITH MATRIX-M™ ADJUVANT.NOVAVAX INC - PHASE 1/2 TRIAL WILL BE CONDUCTED IN AUSTRALIA AT UP TO 12 STUDY SITES, WITH RESULTS EXPECTED DURING FIRST HALF OF 2022.

Novavax Appoints Biopharmaceutical Veterans Jim Kelly As Chief Financial Officer

Aug 16 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX APPOINTS BIOPHARMACEUTICAL VETERANS JIM KELLY AS CHIEF FINANCIAL OFFICER AND NASIR EGAL, PH.D., AS SENIOR VICE PRESIDENT OF QUALITY ASSURANCE.NOVAVAX APPOINTS BIOPHARMACEUTICAL VETERANS JIM KELLY AS CHIEF FINANCIAL OFFICER AND NASIR EGAL, PH.D., AS SENIOR VICE PRESIDENT OF QUALITY ASSURANCE.NOVAVAX INC - ANNOUNCED APPOINTMENT OF JIM KELLY AS EXECUTIVE VICE PRESIDENT, CHIEF FINANCIAL OFFICER (CFO) AND TREASURER.

Novavax Executive Says Co Has 'Tens Of Millions' Of Shots Already Made; Not Concerned They Will Expire Before They Can Be Used: Conf Call

Aug 5 (Reuters) - Novavax Inc <NVAX.O>::NOVAVAX EXECUTIVE SAYS MIGHT PRIORITIZE LOW INCOME COUNTRIES FOR INITIAL VACCINE SUPPLY WHERE THEY WILL BE ABLE TO SUPPORT CRITICAL UNMET DEMAND FOR PRIMARY VACCINATIONS: CONF CALL.NOVAVAX EXECUTIVE SAYS NOVAVAX HAS 'TENS OF MILLIONS' OF SHOTS ALREADY MADE AND NOT CONCERNED THEY WILL EXPIRE BEFORE THEY CAN BE USED: CONF CALL.

Novavax Says COVID-19 Vaccine Booster Data Showed 4-Fold Increase In Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination

Aug 5 (Reuters) - Novavax ::NOVAVAX - COVID-19 VACCINE BOOSTER DATA DEMONSTRATED 4-FOLD INCREASE IN NEUTRALIZING ANTIBODY LEVELS VERSUS PEAK RESPONSES AFTER PRIMARY VACCINATION.NOVAVAX - SIX-FOLD INCREASE IN CROSS-REACTIVE FUNCTIONAL ANTIBODIES TO DELTA VARIANT COMPARED TO PRIMARY VACCINATION SERIES.NOVAVAX - SINGLE BOOSTER DOSE AT 6 MONTHS OF NVX-COV2373 INCREASED WILD-TYPE NEUTRALIZING ANTIBODIES MORE THAN 4-FOLD VERSUS PRIMARY VACCINATION SERIES.NOVAVAX - ANALYSIS OF SERA FROM PRIMARY VACCINATION SERIES SHOWED CROSS-REACTIVE FUNCTIONAL ANTIBODIES TO ALPHA, BETA AND DELTA VARIANTS.NOVAVAX - WILD-TYPE NEUTRALIZATION RESPONSES INCREASED ABOUT 4.3-FOLD COMPARED TO THE PEAK RESPONSE SEEN AFTER DOSE 2.NOVAVAX - VERY HIGH LEVELS OF FUNCTIONAL ANTIBODIES TO THE ALPHA (B.1.1.7), BETA (B.1.351) AND DELTA VARIANTS WERE INDUCED BY BOOSTING WITH NVX-COV2373.NOVAVAX - 28 DAYS FOLLOWING BOOSTING, ANTI-SPIKE IGG INCREASED ABOUT 4.6-FOLD COMPARED TO PEAK RESPONSE SEEN AFTER SECOND DOSE.Further company coverage: NVAX.O. ((Reuters.Briefs@thomsonreuters.com;)).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up